Nurul Akmaryanti Abdullah

Dr. Nurul Akmaryanti Abdullah

Universiti Putra Malaysia
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2021 in Molecules
Verified
Journal Article
Open access
PDF file
NANurul Akmaryanti Abdullah
Nurul Akmaryanti Abdullah
NUR FARIESHA MD HASHIMNUR FARIESHA MD HASHIM
NUR FARIESHA MD HASHIM
AAAula Ammar
Aula Ammar
NZNoraina Muhamad Zakuan
Noraina Muhamad Zakuan
Cancer is one of the leading causes of death worldwide, with a mortality rate of more than 9 million deaths reported in 2018. Conventional anti-cancer therapy can greatly improve survival however treatment resistance is still a major problem especially in metastatic disease. Targeted anti-cancer therapy is increasingly used with conventional therapy to improve patients’ outcomes in advanced and metastatic tumors. However, due to the complexity of cancer biology and metastasis, it is urgent to develop new agents and evaluate the anti-cancer efficacy of available treatments. Many phytochemicals from medicinal plants have been reported to possess anti-cancer properties. One such compound is known as oridonin, a bioactive component of Rabdosia rubescens. Several studies have demonstrated that oridonin inhibits angiogenesis in various types of cancer, including breast, pancreatic, lung, colon and skin cancer. Oridonin’s anti-cancer effects are mediated through the modulation of several signaling pathways which include upregulation of oncogenes and pro-angiogenic growth factors. Furthermore, oridonin also inhibits cell migration, invasion and metastasis via suppressing epithelial-to-mesenchymal transition and blocking downstream signaling targets in the cancer metastasis process. This review summarizes the recent applications of oridonin as an anti-angiogenic and anti-metastatic drug both in vitro and in vivo, and its potential mechanisms of action.

25 March 2021 in Investigational New Drugs
Verified
Journal Article
Open access
PDF file
NANurul Akmaryanti Abdullah
Nurul Akmaryanti Abdullah
MIMartyn Inman
Martyn Inman
CMChristopher J. Moody
Christopher J. Moody
SSSarah J Storr
Sarah J Storr
SMStewart Martin
Stewart Martin
Summary: Radiotherapy is an effective treatment modality for breast cancer but, unfortunately, not all patients respond fully with a significant number experiencing local recurrences. Overexpression of thioredoxin and thioredoxin reductase has been reported to cause multidrug and radiation resistance - their inhibition may therefore improve therapeutic efficacy. Novel indolequinone compounds have been shown, in pancreatic cancer models, to inhibit thioredoxin reductase activity and exhibit potent anticancer activity. The present study evaluates, using in vitro breast cancer models, the efficacy of a novel indolequinone compound (IQ9) as a single agent and in combination with ionising radiation using a variety of endpoint assays including cell proliferation, clonogenic survival, enzyme activity, and western blotting. Three triple-negative breast cancer (MDA-MB-231, MDA-MB-468, and MDA-MB-436) and two luminal (MCF-7 and T47D) breast cancer cell lines were used. Results show that treatment with IQ9 significantly inhibited thioredoxin reductase activity, and inhibited cell growth and colony formation of breast cancer cells with IC50 values in the low micromolar ranges. Enhanced radiosensitivity of triple-negative breast cancer cells was observed, with sensitiser enhancement ratios of 1.20–1.43, but with no evident radiosensitisation of luminal breast cancer cell lines. IQ9 upregulated protein expression of thioredoxin reductase in luminal but not in triple-negative breast cancer cells which may explain the observed differential radiosensitisation. This study provides important evidence of the roles of the thioredoxin system as an exploitable radiobiological target in breast cancer cells and highlights the potential therapeutic value of indolequinones as radiosensitisers.***This study was not part of a clinical trial. Clinical trial registration number: N/A

26 August 2020 in Molecules
Verified
Journal Article
Open access
PDF file
HHHamad Ali Hamad
Hamad Ali Hamad
HEHamid Hammad Enezei
Hamid Hammad Enezei
AAAnmar Alrawas
Anmar Alrawas
NZNoraina Muhamad Zakuan
Noraina Muhamad Zakuan
NANurul Akmaryanti Abdullah
Nurul Akmaryanti Abdullah
NUR FARIESHA MD HASHIMNUR FARIESHA MD HASHIM
NUR FARIESHA MD HASHIM
Hypoxia plays a significant role in solid tumors by the increased expression of hypoxia-inducible factor-1α (HIF-1α), which is known to promote cancer invasion and metastasis. Cancer-cell invasion dynamically begins with the degradation of the extracellular matrix (ECM) via invadopodia formation. The chemical substrates that are utilized by hypoxic cells as fuel to drive invadopodia formation are still not fully understood. Therefore, the aim of the study was to maintain MDA-MB-231 cells under hypoxia conditions to allow cells to form a large number of invadopodia as a model, followed by identifying their nutrient utilization. The results of the study revealed an increase in the number of cells forming invadopodia under hypoxia conditions. Moreover, Western blot analysis confirmed that essential proteins for hypoxia and invadopodia, including HIF-1α, vascular endothelial growth factor (VEGF), metallopeptidase-2 (MMP-2), and Rho guanine nucleotide exchange factor 7 (β-PIX), significantly increased under hypoxia. Interestingly, phenotype microarray showed that only 11 chemical substrates from 367 types of substrates were significantly metabolized in hypoxia compared to in normoxia. This is thought to be fuel for hypoxia to drive the invasion process. In conclusion, we found 11 chemical substrates that could have potential energy sources for hypoxia-induced invadopodia formation of these cells. This may in part be a target in the hypoxic tumor and invadopodia formation. Additionally, these findings can be used as potential carrier targets in cancer-drug discovery, such as the usage of dextrin.

9 May 2024 in Life Sciences
Verified
Journal Article
Closed access
NANurul Akmaryanti Abdullah
Nurul Akmaryanti Abdullah
NHNur Fariesha Md Hashim
Nur Fariesha Md Hashim
NZNoraina Muhamad Zakuan
Noraina Muhamad Zakuan
JCJia Xin Chua
Jia Xin Chua

30 June 2020 in Sains Malaysiana
Verified
Journal Article
Closed access
SHSiti Nor Aini Harun
Siti Nor Aini Harun
NANurul Akmaryanti Abdullah
Nurul Akmaryanti Abdullah
NZNoraina Muhamad Zakuan
Noraina Muhamad Zakuan
HHHafizah Abdul Hamid
Hafizah Abdul Hamid
MMMuhammad Zulfadli Mehat
Muhammad Zulfadli Mehat
NUR FARIESHA MD HASHIMNUR FARIESHA MD HASHIM
NUR FARIESHA MD HASHIM

13 May 2026 in Cytotechnology
Verified
Journal Article
Closed access
PDF file
NANurul Akmaryanti Abdullah
Nurul Akmaryanti Abdullah
AAAnis Hazirah Azman
Anis Hazirah Azman
QCQiao Yi Chong
Qiao Yi Chong
SSSharah Muhammad Shan
Sharah Muhammad Shan
NUR FARIESHA MD HASHIMNUR FARIESHA MD HASHIM
NUR FARIESHA MD HASHIM
NZNoraina Muhamad Zakuan
Noraina Muhamad Zakuan